Safe and cost-effective vaccine delivery

Recombinant measles vaccines are based on the Edmonston Zagreb (EZ) virus strain and are among the safest measles vaccines in the world. These vaccines have been administered successfully as an aerosol without any reported side effects.

Due to their safety profile, vaccines based on the recombinant measles virus vector could also potentially be used to protect children against a number of different diseases—such as measles, malaria and AIDS—with a single immunization. Recombinant measles virus vaccines are among the safest of the new generation of live recombinant multivalent vaccines.

Crucell’s production experience with the standard measles virus vaccine allows the cost-effective and efficient manufacture of large quantities of recombinant measles virus vectors.

Highly immunogenic vaccines

The live recombinant measles virus vaccine induces long-lasting immunity against measles after a single administration. Vaccine candidates against hepatitis B, HIV, West Nile virus and the respiratory virus SARS have been constructed successfully using the measles virus vector. In preclinical vaccine models, this vector has induced potent neutralizing antibodies and cellular immunity. The immune responses elicited by the recombinant measles virus vector were long-lasting and comparable to the parenteral (injectable) measles virus vaccine.

From bench to clinic

Crucell has fully operational BSL class II laboratories with an integrated capacity to produce substantial quantities  of recombinant measles virus vaccine candidates. Process development for the production of recombinant measles virus vector–based vaccines has been established. The research group has fully adapted the manufacturing protocols and developed in-house standard operating protocols for this application. Crucell currently has manufacturing capacity for the production of more than 15 million doses of measles virus vaccine.